
Референции:
1. Rozenblum AB et al. J Thorac Oncol 2017; 12: 258–268.
2. Schwaederle M, Kurzrock R. Oncoscience 2015; 2: 779–780.
3. Mansinho A et al. Expert Rev Anticancer Ther 2017; 17: 563–565.
4. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
5. Drilon A et al. Clin Cancer Res 2015;21:3631–3619.
6. Hirsch FR et al. Lancet 2016; 388: 1012–1024.
7. Baumgart M. Am J Hematol Oncol 2015; 11: 10–13.
8. Chakravarty D et al. JCO Precis Oncol 2017; doi: 10.1200/PO.17.00011.
9. Global Oncology Trends Report 2018. Report by IQVIA Institute for Human Data Science 2019. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019 (Accessed January 2023).
10. Gagan J, Van Allen EM. Genome Med 2015; 7: 80.
11. Schrock AB et al. Clin Cancer Res 2016; 22: 3281–3285.
12. Rankin A et al. Oncologist 2016; 21: 1306–1314.
13. Suh JH et al. Oncologist 2016; 21: 684–691.
14. Zhao P et al. J Hematol Oncol 2019; 12: 54.
15. Abida W et al. JAMA Oncol 2019; 5: 471–478.
16. Kok M et al. ESMO Open 2019; 4(Suppl 2): e000511.
17. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer v. 1 2023 — Sept 16, 2022, Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459 (Accessed January 2023)
18. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer (Accessed January 2023).
19. FDA approves pembrolizumab for adults and children with TMB-H solid tumors, 2020. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (Accessed January 2023).
20. Gandara DR et al. Nat Med 2018; 24: 1441–1448.
21. Yarchoan M et al. JCI Insight 2019; 4: e126908
22. Marabelle A et al. Ann Oncol. 2019;30(suppl_5):v475-v532.
23. Socinski M. Ann Oncol 2019; 30(suppl_5): v851–v934.
24. Khagi Y et al. Clin Cancer Res 2017; 23: 5729–5736.
25. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung
Cancer v 1.2023 — Dec 22, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed January 2023).
26. Kalemkerian GP et al. J Clin Oncol 2018; 36: 911–919.
27. Lindeman NI et al. J Mol Diagn 2018; 20: 129–159.